Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin L. Costello, MD, Adam D. Cohen, MD, Krina K. Patel, MD, Syed S Ali, MD, Jesus G. Berdeja, MD, Nina Shah, MD, Siddhartha Ganguly, MD, Mehmet Hakan Kocoglu, MD, Mehrdad Abedi, MD, Eric M. Ostertag, MD PhD, Chris E Martin, PhD, Majid Ghoddussi, PhD, Devon J Shedlock, PhD, Joanne McCaigue, M.S., Hamid Namini, PhD, Sreeni Yalamanchili, Matthew A. Spear, MD, Tara K. Gregory, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142695

Published: 2020

Journal Articles

Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-142974

Published: 2020

Journal Articles

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Michael Scordo, MD, Lihua E Budde, MD PhD, Mehrdad Abedi, MD, Carolyn Mulroney, MD, Bita Fakhri, MDMPH, Attaphol Pawarode, MDPhD, Bhagirathbhai Dholaria, MBBS, Edward Kavalerchik, MD, Sanjay K. Aggarwal, MD, Muzaffar H. Qazilbash, MD, Paul Finnegan, MD, Sergio A. Giralt, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137257

Published: 2020

Journal Articles

Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Disease Registry

Gail J. Roboz, MD, Christopher R. Cogle, Daniel A. Pollyea, Mehrdad Abedi, MD, Michael A. Thompson, MD PhD, Melissa Nifenecker, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Michelle Little, Harry P. Erba

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-135877

Published: 2020

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Samantha C Fisch, BS, Brian A Jonas, MD PhD, Joseph Tuscano, MD, Aaron Seth Rosenberg, MD, Rasmus T Hoeg, MD, Mehrdad Abedi, MD

Blood (2019) 134 (Supplement_1): 3884.

https://doi.org/10.1182/blood-2019-121991

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 1922.

https://doi.org/10.1182/blood-2019-127743

Published: 2019

Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 897.

https://doi.org/10.1182/blood-2018-99-111531

Published: 2018

Journal Articles

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A. Jonas, MD PhD, Peter T. Curtin, MD, Gary J. Schiller, MD, Deepa Jeyakumar, MD, Matthew J. Wieduwilt, MD PhD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Helen Chow, MD, Leslie G. Oesterich, MD, Aaron C. Logan, MD PhD

Blood (2018) 132 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2018-99-119237

Published: 2018

Journal Articles

Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect ® MDS/AML Disease Registry

Sudipto Mukherjee, MD PhD MPH, Mehrdad Abedi, MD, Harry P. Erba, MD PhD, Daniel A Pollyea, MD, Gail J. Roboz, MD, Michael A. Thompson, MD PhD FASCO, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 4736.

https://doi.org/10.1182/blood-2018-99-112935

Published: 2018

Journal Articles

Effect of Autologous Hematopoietic Stem Cell Transplant (aHSCT) on the Development of Second Primary Malignancies (SPM) in Multiple Myeloma Patients

Aaron Seth Rosenberg, MD, Ann M Brunson, MS, Joseph M Tuscano, MD, Brian A Jonas, MD PhD, Mehrdad Abedi, MD, Ted Wun, MD FACP, FRCPA, Theresa H.M. Keegan, PhD MS

Blood (2017) 130 (Supplement 1): 332.

https://doi.org/10.1182/blood.V130.Suppl_1.332.332

Published: 2017

Journal Articles

A Phase 1 Study of Everolimus and Bendamustine in Patients with Relapsed or Refractory Lymphoid Malignancies and Myeloma

Julian R Davis, MD MA, Brian A Jonas, MD PhD, Joseph M Tuscano, MD, Aaron Seth Rosenberg, MD, Mehrdad Abedi, MD

Blood (2017) 130 (Supplement 1): 4038.

https://doi.org/10.1182/blood.V130.Suppl_1.4038.4038

Published: 2017

Journal Articles

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A Jonas, MD PhD, Aaron C. Logan, MDPhDMPhil, Deepa Jeyakumar, MD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Matthew J. Wieduwilt, Leslie G. Oesterich, MD, Peter T. Curtin, MD

Blood (2017) 130 (Supplement 1): 2973.

https://doi.org/10.1182/blood.V130.Suppl_1.2973.2973

Published: 2017

Journal Articles

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Blood (2016) 128 (22): 3548.

https://doi.org/10.1182/blood.V128.22.3548.3548

Published: 2016

Journal Articles

The Impact of Age and Body Fat on Graft-Versus-Host Disease (GVHD) in Mice

Chien-Chun Steven Pai, Mingyi Chen, MD PhD, Lam Khuat, Annie Mirsoian, Anthony E Zamora, Steven Grossenbacher, Christine Mall, Arta Monjazeb, MDPhD, Julian Perks, PhD, Shuaib Juma, Mehrdad Abedi, MD, William J Murphy, PhD

Blood (2014) 124 (21): 1100.

https://doi.org/10.1182/blood.V124.21.1100.1100

Published: 2014

Journal Articles

Therapeutic Effects of MLN4924 on Sclerodermatous Chronic Graft Versus Host Disease

Chien-Chun Steven Pai, Mingyi Chen, MD PhD, Anthony E Zamora, Lam Khuat, Steven Grossenbacher, William J Murphy, PhD, Mehrdad Abedi, MD

Blood (2014) 124 (21): 3816.

https://doi.org/10.1182/blood.V124.21.3816.3816

Published: 2014

Journal Articles

Organ-Specific Protection By Bortezomib On The Treatment Of Cutaneous Chronic and Acute GvHD

Chien-Chun Pai, Annie Mirsoian, Steven Grossenbacher, Erik Ames, Kai Sun, MD.PhD, Mingyi Chen, MD, PhD, Bruce R Blazar, MD, Mehrdad Abedi, MD, William J Murphy, PhD

Blood (2013) 122 (21): 4473.

https://doi.org/10.1182/blood.V122.21.4473.4473

Published: 2013

Journal Articles

Mac-1 and F4/80 Surface Markers Are Present on Murine Hematopoietic Stem Cells.

Toska J. Zomorodian, MD, Debbie Greer, Kyle Wood, Bethany Foster, Delia Demers, Kevin Johnson, Peter J. Quesenberry, MD, Mehrdad Abedi, MD

Blood (2006) 108 (11): 1677.

https://doi.org/10.1182/blood.V108.11.1677.1677

Published: 2006

Journal Articles

Dose Dense Dreifach* Melphalan100 for Multiple Myeloma.

David Berz, MD, Elise M. McCormack, MD, Eric S. Winer, MD, Patricia Karwan, RNP, Gerald Colvin, DO, Ritesh Rathore, MD, Larry Lum, MD, Mehrdad Abedi, MD, Gerald Elfenbein, MD, Peter J. Quesenberry, MD

Blood (2006) 108 (11): 5465.

https://doi.org/10.1182/blood.V108.11.5465.5465

Published: 2006

NARROW

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect ® MDS/AML Disease Registry

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect ® MDS/AML Disease Registry

Effect of Autologous Hematopoietic Stem Cell Transplant (aHSCT) on the Development of Second Primary Malignancies (SPM) in Multiple Myeloma Patients

A Phase 1 Study of Everolimus and Bendamustine in Patients with Relapsed or Refractory Lymphoid Malignancies and Myeloma

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

The Impact of Age and Body Fat on Graft-Versus-Host Disease (GVHD) in Mice

Therapeutic Effects of MLN4924 on Sclerodermatous Chronic Graft Versus Host Disease

Organ-Specific Protection By Bortezomib On The Treatment Of Cutaneous Chronic and Acute GvHD

Mac-1 and F4/80 Surface Markers Are Present on Murine Hematopoietic Stem Cells.

Dose Dense Dreifach* Melphalan100 for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only